◎ Sugi Atlas

Atlas / Drug / Endoxifen

Endoxifen

drug
On this page

Also known as NSC-749798Z-endoxifen(Z)-EndoxifenEndoxifinENDOXIFEN HCL

Summary

Endoxifen (CHEMBL1093458) is a phase-3 clinical-stage small molecule targeting CYP19A1; indicated across 6 conditions including bipolar disorder and ductal breast carcinoma in situ.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (CYP19A1)
  • Indications: 6 conditions
  • Clinical trials: 10
  • Chemistry: 373.5 Da · C25H27NO2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1093458
NameEndoxifen
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID10090750
Molecular formulaC25H27NO2
Molecular weight373.5
InChIKeyMHJBZVSGOZTKRH-IZHYLOQSSA-N

SMILES: CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3

IUPAC name: 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol

Also known as: Endoxifen, NSC-749798, Z-endoxifen, endoxifen, (Z)-Endoxifen, Endoxifin, ENDOXIFEN, ENDOXIFEN HCL, Endoxifen HCl

Patent coverage: 209 distinct patent families (523 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CYP19A1CYP19A1Inhibition5.220%P11511

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Aromatase, Estrogen receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ESR17.52IC5030nMCHEMBL_ACT_24377199
CYP19A15.22IC506000nMCHEMBL_ACT_13319670
CYP19A15.22IC506000nMCHEMBL_ACT_16620043
CYP19A15.21IC506100nMCHEMBL_ACT_19201328

Target pathways

Aggregated over 1 target gene(s): CYP19A1.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Estrogen biosynthesis1CYP19A1
Endogenous sterols1CYP19A1
Defective CYP19A1 causes AEXS1CYP19A1

Dominant GO biological processes

GO termTargets
negative regulation of chronic inflammatory response1
steroid biosynthetic process1
estrogen biosynthetic process1
androgen catabolic process1
obsolete syncytium formation1
female gonad development1
negative regulation of macrophage chemotaxis1
sterol metabolic process1
female genitalia development1
mammary gland development1
response to estradiol1
uterus development1
prostate gland growth1
testosterone biosynthetic process1
positive regulation of estradiol secretion1

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
bipolar disorder3MONDO:0004985EFO:0009963
ductal breast carcinoma in situ2MONDO:0005023EFO:0000432
angiosarcoma2MONDO:0016982EFO:0003968
breast neoplasm2MONDO:0021100MONDO:0007254
neoplasm1MONDO:0005070EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

PhaseTrials
PHASE26
PHASE13
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04315792PHASE3COMPLETEDEvaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
NCT01042379PHASE2RECRUITINGI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT02311933PHASE2ACTIVE_NOT_RECRUITINGTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
NCT05607004PHASE2RECRUITING(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT06075953PHASE2RECRUITINGDCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT04616430PHASE2COMPLETEDTopical Endoxifen in Women
NCT05068388PHASE2COMPLETEDEffect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
NCT01327781PHASE1ACTIVE_NOT_RECRUITINGZ-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
NCT03317405PHASE1ACTIVE_NOT_RECRUITINGPhase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
NCT01273168PHASE1COMPLETEDEndoxifen in Adults With Hormone Receptor Positive Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 67 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

40 molecules share ≥1 primary target. Top 40 by shared-target count:

MoleculeSourceStatusShared targets
AMINOGLUTETHIMIDEChEMBLPhase 4 (approved)CYP19A1
ANASTROZOLEChEMBLPhase 4 (approved)CYP19A1
CLOTRIMAZOLEChEMBLPhase 4 (approved)CYP19A1
ESTRONEChEMBLPhase 4 (approved)CYP19A1
EXEMESTANEChEMBLPhase 4 (approved)CYP19A1
FLUCONAZOLEChEMBLPhase 4 (approved)CYP19A1
FLUOROURACILChEMBLPhase 4 (approved)CYP19A1
KETOCONAZOLEChEMBLPhase 4 (approved)CYP19A1
LETROZOLEChEMBLPhase 4 (approved)CYP19A1
MICONAZOLEChEMBLPhase 4 (approved)CYP19A1
NIMESULIDEChEMBLPhase 4 (approved)CYP19A1
OSILODROSTATChEMBLPhase 4 (approved)CYP19A1
POSACONAZOLEChEMBLPhase 4 (approved)CYP19A1
TESTOLACTONEChEMBLPhase 4 (approved)CYP19A1
TESTOSTERONEChEMBLPhase 4 (approved)CYP19A1
DOCONEXENTChEMBLPhase 3CYP19A1
ICOSAPENTChEMBLPhase 3CYP19A1
QUERCETINChEMBLPhase 3CYP19A1
RESVERATROLChEMBLPhase 3CYP19A1
2-METHOXYESTRADIOLChEMBLPhase 2CYP19A1
AZALANSTATChEMBLPhase 2CYP19A1
DAIDZEINChEMBLPhase 2CYP19A1
DEXFADROSTATChEMBLPhase 2CYP19A1
DOCOSAPENTAENOIC ACIDChEMBLPhase 2CYP19A1
FADROZOLEChEMBLPhase 2CYP19A1
FLAVONEChEMBLPhase 2CYP19A1
FORMESTANEChEMBLPhase 2CYP19A1
GENISTEINChEMBLPhase 2CYP19A1
IROSUSTATChEMBLPhase 2CYP19A1
LIAROZOLEChEMBLPhase 2CYP19A1
LINOLEIC ACIDChEMBLPhase 2CYP19A1
LUTEOLINChEMBLPhase 2CYP19A1
OLEIC ACIDChEMBLPhase 2CYP19A1
PINOCEMBRINChEMBLPhase 2CYP19A1
PLOMESTANEChEMBLPhase 2CYP19A1
ROGLETIMIDEChEMBLPhase 2CYP19A1
STANOLONEChEMBLPhase 2CYP19A1
URSOLIC ACIDChEMBLPhase 2CYP19A1
VOROZOLEChEMBLPhase 2CYP19A1
FulvestrantPubChemApprovedCYP19A1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot